Clarivate - Earnings Call - Q2 2025

Executive Summary

• Q2 revenue of $621.4M beat S&P Global consensus of $589.4M*, and adjusted diluted EPS of $0.18 exceeded the $0.174* consensus; management reaffirmed full-year 2025 guidance and indicated revenue should skew toward the top end of the range with adjusted EBITDA margin around ~41%.
• Organic trends improved: organic revenue grew 0.5% YoY, recurring organic revenue grew 0.8% YoY, and organic ACV rose 1.3% YoY; recurring revenue mix reached 88% in H1, up 800 bps vs FY24, driven by the shift away from transactional sales and improved renewals.
• Segment highlights: A&G posted H1 2% organic ACV and subscription growth with a 96% renewal rate; IP returned to organic growth in patent annuities; LS&H saw a return to organic ACV growth in H1, aided by Cortellis enhancements and AI features.
• Capital allocation and balance sheet: Q2 free cash flow was $50.3M; CLVT repurchased 11.5M shares in Q2 (H1 repurchases $100M); company refinanced $500M of 2026 secured notes into a 2031 term loan to extend maturities.

What Went Well and What Went Wrong

• What Went Well

  • Recurring mix and renewals strengthened: H1 organic recurring mix reached 88% (+800 bps vs FY24) and the overall renewal rate improved to 93%; A&G renewals were 96% with ~75% of 2025 A&G subscriptions renewed by end-July.
  • Segment execution: IP annuities returned to organic growth in H1; LS&H ACV turned positive, helped by AI-enabled Cortellis product improvements and stronger retention; A&G delivered 2% H1 organic ACV and subscription growth.
  • Cost discipline and margins: Adjusted EBITDA margin held at ~42% in Q2 (42.1%) and improved 50 bps YoY in H1 to 40.7% despite revenue headwinds from disposals/divestitures.

• What Went Wrong

  • Reported revenue declined YoY due to disposals/divestitures; Q2 revenue of $621.4M was down 4.4% YoY on inorganic actions despite modest organic growth.
  • Transactional revenue pressure persisted (down 21.5% YoY in Q2), primarily from product wind-downs in A&G aligned with the subscription-first strategy.
  • Free cash flow conversion moderated in Q2 (19.2%) on lower adjusted EBITDA and higher one-time costs related to the Value Creation Plan; one disposal timing extended by ~6 months at customers’ request.

Transcript

Operator (participant)

Thank you for standing by. My name is Jordan, and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Clarivate Second Quarter 2025 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there'll be a question-and-answer session. If you'd like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you'd like to withdraw your question, press star one again. Thank you. I would now like to turn the call over to Mark Donohue, Vice President of Investor Relations. Please go ahead.

Mark Donohue (VP of Investor Relations)

Thank you, Jordan, and good morning everyone. Thank you for joining us for the Clarivate Second Quarter 2025 Earnings Conference Call. As a reminder, this call is being recorded and webcast, and is copyrighted property of Clarivate. Any rebroadcast of this information in whole or in part without prior written consent of Clarivate is prohibited, and the accompanying earnings call presentation is available on the Investor Relations section of the company's website. During our call, we may make certain forward-looking statements within the meaning of the applicable securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the business or developments in Clarivate's industry to differ materially from the anticipated results, performance, achievements, or developments expressed or implied by such forward-looking statements.

Information about the factors that cause actual results to differ materially from anticipated results or performance can be found in Clarivate's filings with the SEC and on the company's website. Our discussion will include non-GAAP measures or adjusted numbers. Clarivate believes non-GAAP results are useful in order to enhance the understanding of our ongoing operating performance, but they are supplemental to and should not be considered in isolation from or as a substitute for GAAP financial measures. Reconciliation of these measures to GAAP measures is available in our earnings release and supplemental presentation on our website. With me today are Matti Shem Tov, Chief Executive Officer, and Jonathan Collins, our Chief Financial Officer. After prepared remarks, we'll open the call to your questions. With that, it's a pleasure to turn the call over to Matti.

Matti Shem Tov (CEO)

Good morning everyone, and thank you for joining us. We reported solid second quarter financial performance and delivered growth in our key metrics. We also made progress on the Value Creation Plan, including AI-led product innovation, improving sales execution, and enhancing operational efficiency. On slide six, in the second quarter, we demonstrated our strategic positioning within the market. Organic ACV grew 1.3% compared to the prior year period and improved 40 basis points from the end of last year. This was driven by an important improvement in the subscription book due to higher renewal rates and new business wins. Total organic revenue in the second quarter grew 50 basis points, and recurring organic revenue grew almost 1%. Adjusted EBITDA margin for the first half of the year increased 50 basis points to 41%, driven by internal cost efficiencies.

Free cash flow continued to be strong as we generated $50 million in the second quarter and $161 million for the first six months of this year. I'd like to highlight that all of our segments showed improvement for the first half of the year. Our A&G business delivered 2% organic ACV and subscription revenue growth. IP returned to organic growth in patent annuities and is well positioned to benefit from AI tailwind, and Life Science & Health returned to organic ACV growth. With a solid first half, we are reaffirming our full year 2025 outlook. Jonathan will cover the financial result in more detail shortly. On slide seven, our Value Creation Plan was launched in the fall of 2024, and it is on track with measurable progress across all key initiatives and KPIs.

We have launched all major business optimization programs to increase core subscription and recurring revenue, which is enhancing sales predictability. We have completed most of the major operating model changes within our sales organization to improve new business generation, customer engagement, and retention. Since the launch of the VCP last October, we have delivered 10 cutting-edge product and AI-powered capabilities while focusing on developing AI-enabled world-class subscription-based solutions in partnership with customers. We are undertaking strategic review to assess alternatives across the business. If you turn to slide eight, I'll provide an update on the VCP, starting with the A&G segment. Our proactive business model optimization, coupled with decades of experience in delivering data and analytics solutions to our clients, has strategically positioned us to anticipate and adapt to current market dynamics. We are on track to discontinue transactional sales of digital collections and books over the next year.

This shift away from transactional sales is increasing recurring revenue growth by transitioning some of the business to the new ProQuest eBooks product and other content solution subscriptions. We are pleased with the early adoption, with over 70 wins to date and hundreds of customers currently evaluating this new model. Following this change in strategy, A&G subscription revenue now constitutes 93% of the total segment revenue, excluding disposal, up from 79% in the prior year period. In the first half of 2025, we have achieved a 96% renewal rate in A&G. This is an impressive result considering the macro backdrop characterized by reduction in the U.S. federal agency contract, increased constraints on higher education research funding, and potential additional university budget cuts. It is also noteworthy that, as at the end of July, 75% of global A&G subscriptions for the full year is successfully renewed.

This is in line with last year's renewal pace. We continue to successfully invest in innovation across the A&G product portfolio with a focus on AI. We are very pleased by our success so far in product launches and customer adoption. More than 4,800 institutions have already adopted our AI tools to strengthen research support, increase operational efficiency, and enhance student engagement. On slide nine, our partnership within A&G continues to grow, including a recent multi-year agreement with the Canadian Research Knowledge Network that will provide 55 universities greater access to the Web of Science, fostering enhanced research collaboration and impact. We are also accelerating progress with the next-generation agentic AI solution. AI agents can independently plan and execute multi-step processes by interacting with users, data sources, and tools.

The expansion of our agentic AI platform marks a significant milestone as we implement responsible agentic AI to accelerate research and learning workflow. Our initial launch of the literature review agent in the Web of Science exemplifies this pioneering approach. The agent converses with the researcher to understand the research goals, then customizes a specific literature review scope and defines the proper output. This personalized interactive experience keeps the researcher in the center, which closely mimics working with a human assistant. Finally, we are very pleased that Outsell, a leading research advisory firm in B2B technology, data, and information services, recognizes Clarivate AI leadership among major scholarly research organizations, underscoring our position at the forefront of developing user-facing AI agentic tools. Moving to the Intellectual Property segment on slide 10.

After a challenging few years, our patent renewal business returned to growth this year, with organic recurring revenue rising by about 1.5% in the first six months of 2025. The market-wide surge in AI innovation across industries is driving sustained growth in registered IP. We believe this trend will create favorable conditions for our patent renewal business. As an example, in the past year alone, patent filings for AI inventions have grown five-fold compared to pre-ChatGPT levels. In addition, AI has the potential to double innovation output and build a more defensible IP portfolio for industry powered by IP and scientific research. The takeaway is that this strong market tailwind, driven by the proliferation of AI innovation and technology adoption, is fueling our work with customers, empowering them to achieve higher levels of efficiency and IP creation.

Our IP segment is well positioned to capture this growth as we continue to lead at the intersection of technology, innovation, and IP. Going to slide 11, during the second quarter, IPfolio, our industry-leading cloud-based IP Management Software platform designed for corporate intellectual property teams, grew new customers, new clients, and partnerships over 50% year-over-year across global markets, including South Korea and Japan. We are now broadening and accelerating IPfolio adoption across multiple industries, including the pharmaceutical and large law firms. Our expertise and comprehensive solutions have enabled clients such as Winbond to enhance their IP management practices and gain meaningful insights into emerging trends in the IP management transition. This morning, we have announced that Maroun Mourad will join Clarivate as President of the IP segment effective September 8, 2025.

He'll join us from Verisk Analytics, where he is the President for the Claim Solution divisions. We are confident that his leadership abilities and expertise will further drive the IP business commitment to fostering innovation and growth. I would like to express my gratitude and appreciation to Gordon Samson for his dedication to the industry and his significant contribution to Clarivate's success. Turning into Life Science & Healthcare segment. In Life Science, we are encouraged that the VCP effort has resulted in a return to organic ACV growth during the first half of this year. We have been expanding our strategic reach, fostering innovation through a subscription-based platform designed to support Life Science & Health customers. Our commitment to develop robust partnerships is demonstrated by the recent extension of a long-term multimillion-dollar agreement with a top 15 global pharmaceutical company.

This achievement validates the importance of our Cortellis and DRG products and services to customers. Additionally, we continue to drive advancements in MedTech by introducing next-generation commercial analytics. The launch of DRG Commercial Analytics 360, a dedicated subscription platform, empowers MedTech organizations to enhance their commercial strategy and execution capabilities. As commercial budgets improve, we believe we will be best positioned to capitalize on an improving environment. On slide 14, Value Creation Plan, I'm pleased that the VCP plan is on track. The first half of this year was marked by accelerated product innovation and a significant number of new product launches and enhancements in the AI capabilities. We anticipate that the momentum of the product release will continue throughout all three segments in the second half of the year.

By integrating AI functionalities into our offering, including Web of Science Research, Derwent, and Cortellis, we aim to further improve outcomes and value for our users. On slide 15, now that you've heard our VCP's driving result across each of our segments, the fourth pillar of our VCP is evaluating strategic alternatives. Earlier this year, we initiated a formal process to enhance execution focus, optimize capital allocation, support future growth, and increase operational effectiveness. We are making progress and have narrowed the scope of the review. We anticipate communicating the results when we will report our year-end financial performance in February 2026. And lastly, slide 16. In closing, we are pleased to see improved revenue performance for the first six months of 2025, driven by organic ACV growth in A&G and Life Sciences segment and the return of growth in the patent renewal business.

The mix of organic recurring revenue to total revenue for the first half of the year is now 88%, an improvement of 800 basis points compared to last year. Our annual renewal rate across our subscription base improved to 93% during the first half of the year compared to 92% for the same period last year. We are moving in the right direction and seeing early indications that our plan is driving improved performance. It is encouraging to witness the initial sign of success, which affirms the effectiveness of our strategies and the dedication of our teams. We remain focused on executing our plan to ensure sustained growth and value creation for all stakeholders. I would like to turn it over to Jonathan. Thank you.

Jonathan Collins (CFO)

Thank you, Matti. Slide 18 is an overview of our second quarter and first half financial results compared with the same periods from the prior year. Q2 revenue was $621 million, bringing the first half to $1.2 billion. The second quarter change from last year was entirely inorganic as a result of the ScholarOne divestiture and the A&G and LS&H business disposals, partially offset by organic growth and foreign exchange. The second quarter net loss was $72 million. The improvement over Q2 of the prior year is driven by the non-cash impairment charge recorded last year that did not recur this year. Adjusted diluted EPS, which excludes items like the impairment, was $0.18. The change over last year is entirely attributed to the divestiture and disposals. Operating cash flow was $116 million in the quarter.

The change compared to last year is entirely driven by adjusted EBITDA, as an improvement in working capital was offset by higher payments of one-time costs associated with implementing the Value Creation Plan. Please turn with me now to page 19 for a closer look at the drivers of the second quarter top and bottom line changes from the prior year. I'm pleased to share this morning that the business grew organically for the second quarter in a row, and margins remained at approximately 42%. This was driven by four primary factors. First, our recurring organic growth increased 20 basis points sequentially in the second quarter to nearly 1%, as our subscription business returned to growth following the inflection in our ACV in the first half of this year.

Careful operating expense management amplified the $3 million of total organic growth, which includes the transactional revenue type, resulting in a $6 million increase in adjusted EBITDA. Second, during Q2, we continued to experience the inorganic impact of the businesses we are disposing of as a part of the Value Creation Plan. The top and bottom line changes of $32 million and $17 million, respectively, impacted both the A&G and LS&H segments. Third, as we've seen in the last couple of quarters, we continue to experience the inorganic impact of the ScholarOne divestiture, lowering revenue by $9 million and adjusted EBITDA by $4 million. Fourth, the U.S. dollar weakened against the basket of foreign currencies, which caused a foreign exchange translation tailwind on the top and bottom lines.

Please turn with me now to page 20 to review how these same drivers impacted the top and bottom line changes for the first half of this year. As Matti noted just a few moments ago, organic growth for H1 has improved by 180 basis points over where we ended last year. This modest growth compared to last year's decline yielded $5 million of total organic growth and $10 million of incremental adjusted EBITDA in the first half. The combined impact of the disposals and divestitures lowered revenue by $64 million and adjusted EBITDA by $30 million over the same period last year. Both the top and bottom lines benefited from foreign exchange in the first half, as the U.S. dollar weakened towards the end of the first quarter.

The net impact of these changes led to a 50 basis point profit margin expansion for the year-to-date results compared to the same period last year. Please turn with me now to page 21 for a look at how the Q2 and H1 adjusted EBITDA converted to free cash flow and how we allocated the capital in a shareholder-friendly manner. Free cash flow was $50 million in the second quarter, bringing the first half to $161 million. The change in the quarter and the half are driven entirely by the adjusted EBITDA impact outlined on the last two pages, as lower working capital requirements were offset by higher one-time costs. We incurred $18 million of one-time costs in Q2 and $42 million in H1, both of which were largely restructuring-related outflows associated with the implementation of the Value Creation Plan.

Cash interest was $92 million and was slightly lower than Q2 of last year, as we continue to recognize the benefit associated with the $200 million of debt we repaid last year. Working capital requirements improved by $15 million in the second quarter and a comparable amount for the first half, and we expect this trend to continue in the second half of the year as implied in our full-year guidance. Cash taxes, capital spending, and other operating outflows were essentially flat compared to the same periods last year. We used the $50 million of free cash flow we generated in the second quarter to repurchase another 11.5 million shares of common stock, bringing the first half buybacks to $100 million, which is about 60% of the capital we had available to allocate. The remaining 40% increased our cash balance, lowering our net debt.

We also took the opportunity during the second quarter to extend a portion of our debt maturity by five years through refinancing a half a billion of our 2026 bonds with a new tranche on our existing Term Loan B facility, which matures in 2031. Shortly after we completed the refinancing, we swapped about 80% of the new tranche from dollars to euros and from a floating to a fixed interest rate. The net impact of the refinancing and swaps is an annual cash interest increase of about $7 million, a favorable outcome in this higher rate environment. Please turn with me now to page 22 for a reminder of our full-year financial guidance ranges for this year, which remain entirely unchanged from the initial guidance we provided in February and affirmed in April.

Beginning at the top of the page, we continue to expect our organic annual contract value to accelerate by approximately 60 basis points to 1.5% at the midpoint of the range as we begin to recognize the benefits of our investments in product innovation. We've made good progress on this in the first half, where we've delivered more than half of the acceleration, about 40 basis points. Based on our performance in the first half, recurring organic growth will likely be in the upper half of our range. The improved organic performance, combined with a weaker U.S. dollar and slower than anticipated attrition in the business disposals, will likely yield revenue near the top end of the range. As a result of the strategic disposals, we expect our recurring revenue mix will improve by about 400 basis points, from 80% to about 84% this year.

It's worth reiterating what Matti indicated earlier in the call. Our organic recurring revenue mix, which excludes the disposals, is already at 88% in the first half of the year. Moving down the page, we expect adjusted EBITDA slightly above the midpoint of the range and our profit margin at approximately 41% due to higher revenues from the disposals and FX, which have lower profit conversions. We continue to anticipate diluted adjusted EPS between $0.60 and $0.70, as the inorganic-driven change in adjusted EBITDA, which I'll detail on the next page, will be partially offset by lower interest expense, as well as the benefit of a lower share count resulting from last year's and the first half's stock repurchases.

Finally, at the bottom of the page, we anticipate free cash flow at about $340 million at the midpoint of the range, as the adjusted EBITDA change will largely be offset by lower interest, working capital, and capital spending. Please turn with me now to page 23 for more details on the full-year top and bottom line changes we're expecting compared to last year. The expected changes in revenue and, to a large extent, adjusted EBITDA this year compared to last year are largely driven by the disposals targeted at optimizing our business model and the divestitures of non-core products and services. We now expect organic growth will be essentially flat, as the growth in the recurring revenue types, both subscription and recurring, will offset the originally anticipated decline in our remaining transactional business.

This represents about a $10 million improvement over our initial indication at the midpoint of the guidance range. We continue to expect a profit headwind in this area of about $20 million, as cost efficiencies will not fully offset inflation and higher incentive compensation expense. The strategic disposals are now expected to lower revenue this year by approximately $125 million, and we're implementing $85 million of operating cost actions, which yield a profit impact of about $40 million. We expect most of the remaining $75 million revenue reduction will take place next year and will have a small profit impact. The top line change for the disposals represents a $15 million improvement over our initial indication. The divestitures of both Valipat and ScholarOne last year will lower revenue by about $40 million and profit by [audio distortion]

Finally, we now anticipate foreign exchange translation will have a negligible impact, as the U.S. dollar has remained weak against other foreign currencies. This represents a $25 million improvement from our initial indication for full-year revenue. Please turn with me now to page 24 to step through the components that will lead to more than 1/3 of the adjusted EBITDA converting to free cash flow. Our outlook for free cash flow remains unchanged at the midpoint of our range. One-time costs are expected to be slightly elevated over last year as we invest to execute the VCP. We expect cash interest to improve by about $10 million over last year as a result of the debt we prepaid. Cash taxes are expected to remain in line with 2024.

We anticipate the change in working capital this year will be negligible, which represents an improvement over last year of about $25 million. While we remain committed to investing in product innovation, the strategic disposals and cost efficiencies will improve capital spending by about $35 million. The net impact of these changes is free cash flow of $340 million at the midpoint of the range and will result in an improvement on the conversion of adjusted EBITDA of about a percentage point. From a capital allocation perspective, we continue to have the flexibility between share repurchases and deleveraging as we move through the second half of the year. In closing, we believe our first half results indicate strong momentum as the Value Creation Plan is taking hold, as evidenced by a few key elements. First, Q2 represents the second quarter of sequential organic ACV and recurring revenue growth acceleration.

Optimizing our business model by disposing of non-core transactional businesses is creating a laser focus on our core recurring products and services, and we now have tangible evidence of the upward trajectory. Each of our segments made meaningful progress in the first half of the year and have a solid outlook for the second half. In A&G, both organic ACV and subscription revenue growth are stable at about 2%, and we have good line of sight to a stable second half despite funding pressure in the U.S. market. In IP, we've seen a clear rebound in the annuity market, our recurring revenue stream, as it returned to growth in the first half after declines in the prior year. In LS&H, our subscription revenue leading indicator, ACV, returned to organic growth as the investments in Cortellis are paying off in the R&D market with higher retention and strong new subsidies.

We made significant progress on the strategic review in the first half by narrowing the focus to a core option and expect to complete this work in the second half and provide the conclusion with our year-end results. I'd like to finish by thanking all of you for listening in this morning. I'm now going to turn the call back over to Jordan to take your questions. As a reminder, please limit yourself to a question and then return to the queue for any additional.

Jordan, please go ahead.

Operator (participant)

Thank you. As a reminder, at this time, I would like to remind everyone, in order to ask a question, press star, then the number one on your telephone keypad. We'll pause for just a moment to compile the Q&A roster. Your first question comes from the line of Manav Patnaik from Barclays. Your line is live.

Manav Patnaik (Analyst)

I had a question on the IP business. I know you talked about the rebound in the IP and annuity market. I think you also talked about being excited about the AI opportunities there. Just a few parts of that. Just the timing of that rebound, how you can capitalize on that AI opportunity. I think I read somewhere that a lot of the, at least, GenAI, new patents, all that kind of activity seems to be more weighted towards China. Just wondering your exposure and capabilities there as well.

Jonathan Collins (CFO)

Yeah, sure, Manav. Thanks for the question. In principle, as new filings and new patents are awarded, on average, it takes a couple or a few years to work its way into the renewals. It varies by jurisdictions, but on average, it's a couple to a few years. This is a trend that we've started to see over the last year or two and think that it's something that could help put some wind into our sails as we move into next year and the following year. There is a clear trend that more patents are being filed related to AI. Overall, this is a good thing for our business. That's what we wanted to highlight and note. To your point, the quantity of patents that have been filed related to AI are a bit disproportionate. Our IP Center for Innovation Research noted that in some of its recent reportings.

We've seen more of it in Asia and particularly in China, but we've certainly seen an uptick in most of the major regions. We think we'll start to see that benefit around the globe over the course of the next few years.

Mark Donohue (VP of Investor Relations)

Thanks, Manav. Next question, please, Jordan.

Operator (participant)

Your next question comes from the line of Tony Kaplan from Morgan Stanley. Your line is live.

Toni Kaplan (Analyst)

Thank you so much. I think earlier this week, we saw a headline that the Department of Commerce is considering changes to the fee structure and filing patents in the U.S. I know there's a lot of moving parts and it's not totally settled yet, but just wanted to understand maybe the potential impacts to your business from the potential change in fee structure and how that plays out. Thanks.

Matti Shem Tov (CEO)

First of all, we've seen this as well. It's very early days. Obviously, there's no definite decision and no definite view on our side. Let's just remind ourselves that we've been in the IP ecosystem for more than two or three decades. We are an integral part of the ecosystem, including collaborating with patent offices worldwide, collaboration with law firms, and with corporates. In a way, we are sitting at the intersection and supporting those institutions. Any change that will be, we are very well positioned to support this change and somehow even take advantage of this change. Yes, this market may be changing and may be not changing, but we've been there for the last 20, 30 years, and even more. We are very well positioned close to our customers. We'll track it.

We'll continue to, as it continues to evolve, then we will be collaborating with our customers and partners on this transition.

Toni Kaplan (Analyst)

Thank you.

Mark Donohue (VP of Investor Relations)

Thank you, Tony. Next question, Jordan.

Operator (participant)

Next question comes from the line of Owen Lau from Oppenheimer. Your line is live.

Owen Lau (Analyst)

Hi. Good morning. Thank you for taking my question. For university funding cuts, which is still a hot topic, I saw that 75% of your 2025 subscriptions have already been renewed in July, which is good. Could you please give us more color on your conversation with your clients about the current situation so far and the outlook for renewal in the second half and going into 2026? Thanks a lot.

Matti Shem Tov (CEO)

I'll start, and then Jonathan may continue. We are looking good on A&G despite all the concerns that we collectively have. 93% of the A&G revenue is now recurring. We have 96% renewal rates. As you mentioned, 75% of the books are already in-house. We don't have anything out of the ordinary with our customers, but let's just remind ourselves of a few things. One, you know our A&G products are central and mission-critical to its organization. I cannot imagine a decent university today without Web of Science and some of the surrounding problems. Any university will need to have an Alma-type solution. We are in pretty good shape on the Web of Science and the ERP Alma things. With regards to the content, as I mentioned in my discussion, we were forward-looking, taking away the discretionary one-time expenditure. This serves us very, very well these days.

We see the uptake of customers who were initially complaining about taking away the one-time purchases. They are now buying more and more of our subscription businesses, the PQ eBooks, the PQ digital collections, which actually serves them very, very well in this current economic climate. We are pretty confident that going ahead, we'll continue to see good and decent renewal rates and uptake of the different A&G offerings. Thank you.

Mark Donohue (VP of Investor Relations)

Thank you, [Gordon] Jordan, next question, please.

Operator (participant)

Your next question comes from the line of Ashish Sapadra. Your line is live.

Will Qi (Analyst)

Hi. Good morning, guys. This is [Will Qi] on for Ashish Sapadra. Congrats on the quarter. I appreciate you guys taking our question. Last quarter, you guys initiated on a new sales incentive plan with a refocus on subscription and recurring revenue. It's been great to see that progress with the renewals tick up. I'm curious to know if you could provide any updates, you know, how that sales momentum has been continuing and any outlook from here. Thank you.

Matti Shem Tov (CEO)

I think we've taken away a lot of hassle from the sales organization. We are very, very focused these days. Subscription, recurring, renewal, price, bringing back new business. Customers, like I've just attended a sales meeting last week in London, and people are very excited. They're very focused. They just do subscription and recurring as opposed to do subscription, one-time, one-time eBooks. It's just complicated. The focus, we're taking away, we took away a lot of complexity out of the organization and focusing on the sales organization. We have a great sales organization. We've done some changes which I've spoken about. Very upbeat about going forward for the rest of the year and for next year as well. Yeah.

Will Qi (Analyst)

Thank you.

Operator (participant)

Just as a reminder, if you'd like to ask a question, press star one on your telephone keypad. Your next question comes from the line of George Tong from Goldman Sachs. Your line is live.

George Tong (Analyst)

Hi, thanks. Good morning. Your clients in the healthcare business saw organic revenue growth positively inflect. Can you give a little bit more color around end market dynamics that you're seeing, and how conversations with pharma and biotech companies have evolved?

Jonathan Collins (CFO)

Yeah, thanks for the question, George. To be clear, what we saw in the second quarter is the subscription business within Life Sciences and Healthcare return to positive organic ACV growth, which is a really good leading indicator for where we would expect subscription revenue for that business to be in the second half of the year. To your point, just a little color on the market. You know we primarily serve R&D and then the commercialization efforts of our life sciences customers. On the R&D side, that market continues to be stable. Spending on our types of solutions has been solid. We attribute the improvement largely to the investments that we have made, primarily in the Cortellis suite of products. Over the course of the last 6-12 months, we've made some really nice strides.

Matti touched on a couple of those new capabilities that have gone into the products. We've embedded AI, made investments in the workflow capabilities of those solutions, and we've seen nice usage and nice retention improvements on those products. We attribute that to the improvement that we've seen in this area. The commercialization part of that market continues to be relatively soft, and that's reflected in the results of our commercialization business. Certainly, stable in R&D, that's where we're really starting to see the traction based on the investments that we've made. Thanks for the question, George.

George Tong (Analyst)

Very helpful. Thank you.

Operator (participant)

Your final question comes from the line of Shlomo Rosenbaum from Stifel. Your line is live.

Adam Parrington (Analyst)

Hi, this is Adam on for Shlomo. Why are disposals taking longer than expected? Is this a customer service focus, a shift towards trying to sell some of the assets, or something else? Thanks.

Matti Shem Tov (CEO)

Oh, it's pretty straightforward. I mean, there's one out of the three disposals. One is taking longer because we simply had some interaction with our customers, and they asked us to extend because it took them longer than we expected to get settled with alternative offerings. We just extended it by six months. It reflects on the setting that specifically on the one-time eBooks, they asked for more time to get organized, and that's the reason. Nothing behind this.

Mark Donohue (VP of Investor Relations)

Thank you very much. That concludes our call for today. If you have any follow-up questions, you can reach out to Investor Relations. Thank you very much.

Matti Shem Tov (CEO)

Thank you.

Operator (participant)

Ladies and gentlemen, that concludes today's call. Thank you all for joining. You may now disconnect.